The Motley Fool
13 Sept 2026, 19:33 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Bristol Myers Squibb faces a major patent cliff in 2028 with the loss of U.S. patent exclusivity for flagship drugs Eliquis and Opdivo. — Loss of exclusivity for primary revenue drivers typically leads to significant earnings declines due to generic competition.
-0.60Analyst forecasts predict Bristol Myers Squibb's earnings per share will drop from $6.95 to $6.56 next year. — Direct downward revision of near-term earnings projections typically pressures stock prices.
-0.40Bristol Myers Squibb is trading at a low valuation of just under 10 times forward earnings with a forward dividend yield near 4%. — Low valuation and high yield can attract value investors and provide a price floor.
+0.30Continue reading
5 related stories
Search tags
The company has executed a series of smaller acquisitions in 2024 and 2025 to strengthen its pipeline in cardiovascular, immunology, and oncology. — Strategic acquisitions help mitigate the impact of patent losses by diversifying revenue streams.
+0.20Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
